[{"orgOrder":0,"company":"Humedix","sponsor":"Kineta","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Partnership","leadProduct":"KVA12.1","moa":"VISTA","graph1":"Oncology","graph2":"IND Enabling","graph3":"Humedix","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Humedix \/ Kineta","highestDevelopmentStatusID":"5","companyTruncated":"Humedix \/ Kineta"}]

Find Clinical Drug Pipeline Developments & Deals by Humedix

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          2024 ACI Convention
                          Not Confirmed
                          2024 ACI Convention
                          Not Confirmed

                          Details : Humedix has secured certain exclusive distribution rights in Korea for products that are commercialized from Kineta's pipeline currently under development including KVA12.1.

                          Brand Name : KVA12.1

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          October 04, 2021

                          Lead Product(s) : KVA12.1

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Kineta

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank